Abattis Bioceuticals Corp. (ATTBF)

[jjr04001]

Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)

Vancouver, British Columbia--(Newsfile Corp. - April 12, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis") is pleased to announce that it has received a Natural Product Number ("NPN") approval for Phyto(NOS)TM. This NPN allows Abattis to manufacture and to sell Phyto(NOS) TM in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)TM in the United States.

Phyto(NOS)TM is an all-natural, patent-pending formulation that naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants that help protect against oxidative cell damage caused by free radicals. Phyto(NOS) TM has applications in a wide range of food, beverage and nutraceutical products.

Abattis Director and product designer, Brazos Minshew, says "I designed Phyto(NOS)TM to deliver bio-active Nitric Oxide to the body in a natural, sustainable and metabolically-friendly manner. Nitrates in the plant-based ingredients of PHYTO[NOS]™ get converted quickly into nitric oxide. This action is faster and doesn’t require enzymes. The benefits are seen with very small quantities of nitrates under conditions of both high and low oxygen."He adds, "In our NÖXX Botanical Blends line of products, PHYTO[NOS]™ is blended with other natural fruit and herb extracts to target specific health concerns by enhancing the benefits and focusing the desired effects in each of our products."

Our market research and outreach within our target markets validates both the need and the demand for the NÖXX Botanical Blends line of products. Early interest from customers and other product developers interested in all-natural nitric oxide support has been very positive. The worldwide market for products where nitric oxide is involved in the mechanism of action is expected to reach US$147 billion in 2019.1

The discovery of the nitric oxide pathway is recognized as a critical advancement in cell signaling and has led to major advancements in many clinical areas that have the ability to transform biotechnology and medicine. Important therapeutic areas for nitric oxide-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. Decreased production and or bioavailability of nitric oxide is recognized as being one of the earliest events in the onset and progression of many diseases.2

ON BEHALF OF THE BOARD

"Rene David"
Rene David, CFO

For further information, contact the Company at [phone] or at [e-mail].